Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1745-6215
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial ; volume:12 ; number:1 ; day:30 ; month:6 ; year:2011 ; pages:1-10 ; date:12.2011
Trials ; 12, Heft 1 (30.6.2011), 1-10, 12.2011
- Urheber
-
Omollo, Raymond
- Beteiligte Personen und Organisationen
-
Alexander, Neal
Edwards, Tansy
Khalil, Eltahir AG
Younis, Brima M.
Abuzaid, Abuzaid A.
Wasunna, Monique
Njoroge, Njenga
Kinoti, Dedan
Kirigi, George
Dorlo, Thomas PC
Ellis, Sally
Balasegaram, Manica
Musa, Ahmed M.
SpringerLink (Online service)
- DOI
-
10.1186/1745-6215-12-166
- URN
-
urn:nbn:de:1111-2016050222282
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Omollo, Raymond
- Alexander, Neal
- Edwards, Tansy
- Khalil, Eltahir AG
- Younis, Brima M.
- Abuzaid, Abuzaid A.
- Wasunna, Monique
- Njoroge, Njenga
- Kinoti, Dedan
- Kirigi, George
- Dorlo, Thomas PC
- Ellis, Sally
- Balasegaram, Manica
- Musa, Ahmed M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Feasibility, acceptance and safety of treating visceral leishmaniasis patients with liposomal amphotericin B in rural Bangladesh
A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure
Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B
Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia
Visceral leishmaniasis complicated with hemophagocytic lymphohistiocytosis and resistant to amphotericin B: a case report
Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
Single-dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
Relationship of serum antileishmanial antibody with development of visceral leishmaniasis, post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse
Mediastinal Lymphadenopathy in Visceral Leishmaniasis
Current and promising novel drug candidates against visceral leishmaniasis
Direct-acting antivirals and visceral leishmaniasis: a case report
Imported visceral leishmaniasis and immunosuppression in seven Norwegian patients
Feasibility, acceptance and safety of treating visceral leishmaniasis patients with liposomal amphotericin B in rural Bangladesh
A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure
Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B
Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia
Visceral leishmaniasis complicated with hemophagocytic lymphohistiocytosis and resistant to amphotericin B: a case report
Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
Single-dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
Relationship of serum antileishmanial antibody with development of visceral leishmaniasis, post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse
Mediastinal Lymphadenopathy in Visceral Leishmaniasis
Current and promising novel drug candidates against visceral leishmaniasis
Direct-acting antivirals and visceral leishmaniasis: a case report
Imported visceral leishmaniasis and immunosuppression in seven Norwegian patients
Feasibility, acceptance and safety of treating visceral leishmaniasis patients with liposomal amphotericin B in rural Bangladesh
A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure
Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B
Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia
Visceral leishmaniasis complicated with hemophagocytic lymphohistiocytosis and resistant to amphotericin B: a case report
Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
Single-dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
Relationship of serum antileishmanial antibody with development of visceral leishmaniasis, post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse
Mediastinal Lymphadenopathy in Visceral Leishmaniasis
Current and promising novel drug candidates against visceral leishmaniasis
Direct-acting antivirals and visceral leishmaniasis: a case report